Page 6

TheLaboratoryReport_Winter2014

New Year, New Milestones for the Houston Methodist Diagnostic Laboratory The rapidly-expanding Houston Methodist Diagnostic Labora-tory (HMDL) has ushered in 2014 with many exciting addi-tions that enhance their ability to provide outstanding refer-ence laboratory services. Added to the HMDL were new clients, new tests, and a new, streamlined billing system and web portal. “We have expanded our client base from Louisiana to California” said Dr. Wayne Chandler, director of HMDL. “Clients are now able to easily order tests online through the expanded and user-friendly website.” Recently-added tests to the online menu include: the Respira-tory Pathogens Assay that rapidly detects most pathogens responsible for upper and lower respiratory tract infections; a genetic screening panel to detect oligodendrogliomas, a dif-ficult to diagnose brain tumor; and a new assay to detect levels of rivaroxaban (Xarelto®), an oral anticoagulant designed to replace traditional warfarin for patients with certain conditions. In addition, new testing modalities are in constant development, and include integration of mass spectrometry, fluorescent in situ hybridization, whole genome sequencing, diagnostic immu-nology, and coagulation assays. To learn more about the HMDL or to order tests, please visit: http://www.houstonmethodist.org/houston-methodist-diag-nostic- laboratories THE LABORATORY REPORT Winter 2014 Page 6 The Houston Methodist Hospital De-partment of Pathology and Genomic Medicine is sponsoring the 2014 Cancer Biomarkers Conference to be held on March 22nd in the Houston Methodist Re-search Institute auditorium. The day-long event will feature talks from leaders in the field of biomarker discovery and applica-tion. This exciting program assembled by co-directors Drs. Philip Cagle and Randall Olsen and associate directors Drs. Bryce Portier and Hidehiro Takei, is a must-attend event for individuals involved or interested in the molecular diagnosis of cancer. The schedule of speakers is provided, but for more information on the conference, or to register for the event, please go to: http:// cancer-biomarkers.org/registration/ Angela N. Bartley, M.D. Department of Pathology St. Joseph Mercy Hospital Patrick Fitzgibbons, M.D. Chair, Cancer Biomarker Reporting Com-mittee, College of American Pathologists Stanley R. Hamilton, M.D. Division Head, Pathology/Lab Medicine, MD Anderson Cancer Center Alexander Lazar, M.D., Ph.D. Director, Sarcoma & Melanoma Molecular Diagnostics, Associate Professor of Pa-thology and Dermatology, MD Anderson Cancer Center Neal Lindeman, M.D. Director, Molecular Diagnostics, Brigham and Women’s Hospital, and Associate Pro-fessor, Pathology, Harvard Medical School Jan Nowak, M.D., Ph.D. Director, Molecular Diagnostics Lab, University of Chicago Pritzker School of Medicine Mark A. Rubin, M.D. Director of the Institute for Precision Medicine, Weill Cornell Medical College Fattaneh Abbas-Zadeh Tavassoli, M.D. Professor of Pathology, Yale School of Medicine SPEAKERS A flow cell for the Illumina MiSeq instrument is used for whole genome sequencing of microbes in our clinical laboratory


TheLaboratoryReport_Winter2014
To see the actual publication please follow the link above